These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36810097)

  • 1. The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130.
    Müller SA; Shmueli MD; Feng X; Tüshaus J; Schumacher N; Clark R; Smith BE; Chi A; Rose-John S; Kennedy ME; Lichtenthaler SF
    Mol Neurodegener; 2023 Feb; 18(1):13. PubMed ID: 36810097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons.
    Pigoni M; Wanngren J; Kuhn PH; Munro KM; Gunnersen JM; Takeshima H; Feederle R; Voytyuk I; De Strooper B; Levasseur MD; Hrupka BJ; Müller SA; Lichtenthaler SF
    Mol Neurodegener; 2016 Oct; 11(1):67. PubMed ID: 27716410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density In Vivo.
    Pratsch K; Unemura C; Ito M; Lichtenthaler SF; Horiguchi N; Herms J
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory.
    Nash A; Gijsen HJM; Hrupka BJ; Teng KS; Lichtenthaler SF; Takeshima H; Gunnersen JM; Munro KM
    Sci Rep; 2021 Jul; 11(1):15084. PubMed ID: 34302009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System.
    Munro KM; Nash A; Pigoni M; Lichtenthaler SF; Gunnersen JM
    J Mol Neurosci; 2016 Nov; 60(3):305-315. PubMed ID: 27456313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.
    Zhu K; Xiang X; Filser S; Marinković P; Dorostkar MM; Crux S; Neumann U; Shimshek DR; Rammes G; Haass C; Lichtenthaler SF; Gunnersen JM; Herms J
    Biol Psychiatry; 2018 Mar; 83(5):428-437. PubMed ID: 28129943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects β-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo.
    Dislich B; Wohlrab F; Bachhuber T; Müller SA; Kuhn PH; Hogl S; Meyer-Luehmann M; Lichtenthaler SF
    Mol Cell Proteomics; 2015 Oct; 14(10):2550-63. PubMed ID: 26139848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
    Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
    J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
    Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
    J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.
    Schmidt A; Hrupka B; van Bebber F; Sunil Kumar S; Feng X; Tschirner SK; Aßfalg M; Müller SA; Hilger LS; Hofmann LI; Pigoni M; Jocher G; Voytyuk I; Self EL; Ito M; Hyakkoku K; Yoshimura A; Horiguchi N; Feederle R; De Strooper B; Schulte-Merker S; Lammert E; Moechars D; Schmid B; Lichtenthaler SF
    J Clin Invest; 2024 Jun; 134(16):. PubMed ID: 38888964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
    [No Abstract]   [Full Text] [Related]  

  • 14. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
    Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
    J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
    Luo X; Yan R
    Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate.
    Kitazume S; Saido TC; Hashimoto Y
    Glycoconj J; 2004; 20(1):59-62. PubMed ID: 14973371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
    Yan R; Vassar R
    Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
    Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
    J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.